ArticleMolecules (Basel, Switzerland)2017
Selenazolinium Salts as "Small Molecule Catalysts" with High Potency against ESKAPE Bacterial Pathogens.
Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- Selenium in Action: Exploring the Biological Wonders of Hydroselenite Salts.Molecules (Basel, Switzerland) · 2025Article
- Article
- Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance.Frontiers in cellular and infection microbiology · 2025Review
- Antimicrobial resistance: use of phage therapy in the management of resistant infections.Molecular biology reports · 2024Review
- Selenium-analogs based on natural sources as cancer-associated carbonic anhydrase isoforms IX and XII inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Chalcogen-Varied Imidazolone Derivatives as Antibiotic Resistance Breakers inAntibiotics (Basel, Switzerland) · 2023Article
- Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity.Pharmaceutics · 2022Article
- Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production.Scientific reports · 2020Article
- Biofilm Eradication by Symmetrical Selenoesters for Food-Borne Pathogens.Microorganisms · 2020Article
- Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Antiviral, Antimicrobial and Antibiofilm Activity of Selenoesters and Selenoanhydrides.Molecules (Basel, Switzerland) · 2019Article
- Selenocompounds as Novel Antibacterial Agents and Bacterial Efflux Pump Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- The Concept of an Ideal Antibiotic: Implications for Drug Design.Molecules (Basel, Switzerland) · 2019Review
- Small Molecule Catalysts with Therapeutic Potential.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In view of the pressing need to identify new antibacterial agents able to combat multidrug-resistant bacteria, we investigated a series of fused selenazolinium derivatives (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.